Qingdao Kangyuan Pharmaceutical Co., Ltd.

Qingdao Jiulong Biopharmaceutical Group operates two API (Active Pharmaceutical Ingredient) plants and two formulation plants in China, along with a newly built factory offering contract manufacturing services. Overseas, the Group owns two pharmaceutical manufacturing enterprises in Germany and Japan, committed to serving the global market. Qingdao Jiulong Biopharmaceutical Co., Ltd. is the professional heparin sodium API manufacturer who has 2 workshops with US-FDA and PMDA approval in china. The company are mainly produce in Heparin Sodium, Heparin Calcium, Dalteparin Sodium, Heparinoid, Enoxaparin Sodium, Chondroitin Sulfate Sodium etc. Please see us more on the website: www.qjbchina.com. Qingdao Kangyuan Pharmaceutical Co., Ltd. is the first enterprise from urine to API with US-FDA approval in China, passed Japan PMDA in 2024. The company are mainly produce in Human Chorionic Gonadotrophin (HCG), Human Menopausal Gonadotrophin (HMG), Follicie Stimulating Hormone (FSH), Urokinase (UK), Ulinastain(UTI), , Protamine Sulfated Chymotrypsin, Hyaluronidase, Hyaluronidase and so on. Please see us more on the website: www.kangyuan.com.cn. Lotus Biopharma GmbH is the enterprise based in Germany, serves as a biopharmaceutical R&D and manufacturing enterprise targeting the European and global markets. Its bioprotein purification production line is scheduled to commence production in 2025 and successfully pass the European GMP inspection in 2026. Additionally, Qingdao Guanlong Bio-pharmaceutical Co., Ltd., another subsidiary of the Group, offers products such as injectable chorionic gonadotropin, injectable urokinase, injectable torasemide, and calcium lactate tablets, as well as contract manufacturing services.